Compare Amphastar Pharmaceuticals Inc (AMPH) vs Modine Manufacturing Company (MOD) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Modine (MOD) trades at $245.91, up 0.99% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong revenue growth to $2.58 billion in 2025, though net income margin compressed to 3.82%. Analyst consensus remains bullish with a $328.80 price target, supported by 10 buy ratings. Recent news highlights Modine's positioning in the AI data center cooling market, with sales projected to grow 60-80% in fiscal 2027.

The outlook is mixed: robust growth in data center demand offers upside, but high valuation multiples (P/E 108.81) and margin pressures pose risks. Investors face volatility from supply chain challenges and competitive threats in the HVAC segment. Wall Street optimism contrasts with technical weakness, suggesting cautious optimism for long-term growth despite near-term headwinds.